[Form 4] Alaunos Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Director Jaime Vieser of Alaunos Therapeutics (TCRT) reported the acquisition of derivative securities in a Form 4 filing. On June 24, 2025, Vieser purchased 250 shares of Series A-2 Convertible Preferred Stock at $4.49 per share.

Key transaction details:

• The preferred stock is convertible to 55,679.29 shares of common stock
• The securities are held in direct ownership
• The preferred stock is perpetual with no expiration date
• Transaction code 'P' indicates an open market purchase

This insider purchase by a director could signal confidence in the company's future prospects. The convertible preferred stock provides potential upside exposure to common stock while offering preferred stockholder benefits.

Positive

• Director Jaime Vieser purchased $1.12M worth of Series A-2 Convertible Preferred Stock (250 shares convertible to 55,679 common shares) at $4.49 per share, demonstrating insider confidence in the company's long-term prospects

Negative

• None.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vieser Jaime

(Last) (First) (Middle)

C/O ALAUNOS THERAPEUTICS, INC.

2617 BISSONNET ST, SUITE 233

(Street)

HOUSTON TX 770005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alaunos Therapeutics, Inc. [ TCRT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A-2 Convertible Preferred Stock	$4.49	06/24/2025		P		250		06/24/2025	(1)	Common Stock	55,679.29	$4.49	250	D

Explanation of Responses:

1. The preferred stock is perpetual and therefore has no expiration date.

	/s/ Melinda Lackey	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction occurred at TCRT on June 24, 2025?

Director Jaime Vieser purchased 250 shares of Series A-2 Convertible Preferred Stock at a price of $4.49 per share on June 24, 2025.

How many common shares can TCRT's Series A-2 Preferred Stock be converted into?

According to the Form 4 filing, the 250 shares of Series A-2 Convertible Preferred Stock are convertible into 55,679.29 shares of TCRT common stock.

What is the conversion price of TCRT's Series A-2 Preferred Stock?

The conversion or exercise price of TCRT's Series A-2 Convertible Preferred Stock is $4.49 per share.

Who is Jaime Vieser at TCRT and what is their role?

Jaime Vieser serves as a Director on the Board of Alaunos Therapeutics, Inc. (TCRT), as indicated by the Form 4 filing which shows their relationship to the issuer as 'Director'.

Does TCRT's Series A-2 Preferred Stock have an expiration date?

No, according to the filing's explanatory notes, the preferred stock is perpetual and therefore has no expiration date.